Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2–positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trialResearch in context

Summary: Background: Trastuzumab deruxtecan (T-DXd; 6·4 mg/kg) is approved for metastatic human epidermal growth factor receptor 2 (HER2)–positive (HER2+) gastric or gastroesophageal junction (GEJ) adenocarcinoma after a trastuzumab-based regimen. We report the final analysis of DESTINY-Gastric06,...

Повний опис

Бібліографічні деталі

Автори:	Zhi Peng, Ping Chen, Jin Lu, Yiye Wan, Yulong Zheng, Feng Ye, Jianwei Yang, Ying Liu, Hongming Pan, Meili Sun, Qingxia Fan, Ying Yuan, Kai Chen, Zhuoer Sun, Han Tian, Ye Xia, Lin Shen
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Elsevier 2025-09-01
Серія:	EClinicalMedicine
Предмети:	HER2+ T-DXd Gastric cancer Gastroesophageal junction adenocarcinoma
Онлайн доступ:	http://www.sciencedirect.com/science/article/pii/S2589537025003360
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!